Related Experiment Video
Updated: Jan 14, 2026
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Hormone replacement therapy and the prevention of cardiovascular disease
1Monash University Department of Medicine, Dandenong Hospital, Victoria, Australia. h.teede@southernhealth.org.au
Insights
Hormone replacement therapy (HRT) shows potential for primary cardiovascular disease (CVD) prevention in women but is not recommended for secondary prevention. Lifestyle changes offer significant CVD risk reduction without HRT risks.
Area of Science:
- Cardiology
- Endocrinology
- Women's Health
Background:
- Cardiovascular disease (CVD) remains a leading cause of death in Western societies.
- Preventive strategies have reduced CVD rates, yet further interventions are needed.
- Hormone replacement therapy (HRT) has been investigated for its cardiovascular effects in post-menopausal women.
Purpose of the Study:
- To evaluate the role of HRT in cardiovascular disease (CVD) prevention.
- To assess the efficacy and risks of HRT in primary and secondary prevention of CVD.
- To compare HRT's potential benefits against lifestyle modification strategies.
Main Methods:
- Review of observational data and controlled trials on HRT and cardiovascular outcomes.
- Analysis of estrogen's cardiovascular effects.
- Assessment of risks associated with HRT, including thrombosis and breast cancer.
Main Results:
- Observational data suggested HRT may reduce CVD in post-menopausal women.
- A controlled trial indicated a specific HRT regimen did not reduce, and may increase, cardiovascular events in women with established CVD, deeming it inappropriate for secondary prevention.
- Lifestyle modification could eliminate 80% of CVD in women without HRT risks.
Conclusions:
- Current evidence is insufficient to recommend HRT solely for CVD prevention.
- HRT is inappropriate for secondary prevention of cardiovascular disease.
- Focus should be on established preventative therapies and further research into HRT and estrogen-receptor modulators is warranted.
Abstract:
Cardiovascular disease (CVD) is the primary killer of both men and women in Western societies. The implementation of preventive strategies has led to a fall in the rate of CVD, but there is still much to be achieved. Proven interventional strategies are largely under-utilized, and the search continues for further promising interventions. HRT appears to reduce CVD in post-menopausal women, based on observational data supported by plethora of evidence for the beneficial cardiovascular effects of estrogen. However, a recent controlled trial in post-menopausal women with established CVD has shown that a specific combined oral HRT regimen did not reduce, and may even contribute to, an early increase in cardiovascular events, suggesting that HRT is inappropriate in secondary prevention. HRT may be useful in the primary prevention of CVD, yet observational data that suggested cardiovascular benefit with HRT also suggests that 80% of CVD in women could be eliminated by lifestyle modification, without the attendant risks of HRT including thrombosis and (potentially) breast cancer. At present, it is arguable that the evidence is inadequate to recommend HRT solely for the purpose of CVD prevention, and that the challenge for the health professional should be appropriate utilization of established preventative therapies, with further research into the potential role of HRT and estrogen-receptor modulators.
